A new challenge to public health has emerged in recent years from potent and untested drugs being sold under the guise of being 'dietary' supplements [1] [2] [3] [4] . Fuelled by growing demand for products promising a better body, enhanced performance, and increased wellbeing, this trend highlights creative marketing strategies used in the illicit supply of drugs.
Nine supplements suspected of containing drugs were analysed as part of investigation for the television programme Spotlight (Broadcasted 31 March 2015 by BBC Northern Ireland). The supplements were bought from high-street shops and from an e-commerce site (Table) . Products were sold as 'fat burners' or 'pro hormones', with packaging often blatantly listing chemical names of drugs.
Ostarine belongs to the group of selective androgen receptor modulators (SARMs) and was found in Product 4. Ostarine is being tested as a medicine, but has not been authorised for marketing. The stimulant 1,3-dimethylamylamine (DMAA) was found in Product 1 and Product 2, and 1,3-dimethylbutylamine (DMBA) was found in Product 3 and Product 8. DMAA was recently identified in 'dietary supplements' and has been associated with adverse events, including acute myocardial infarction, strokes, and deaths [4] . Since regulators have removed DMAA from the market, an analogue DMBA has appeared as a replacement [3] . Products 6, 7, and 9 contained anabolic steroids, some of which have been associated with hepatoxicity [2] . Although advertised as legal 'pro hormones' they are controlled drugs in the UK.
These findings illustrate developments on the market, which now includes 'dietary supplements' containing medicines, 'legal highs', and controlled drugs. Many experienced users are aware of this marketing strategy. However, young or otherwise inexperienced people may be unknowingly exposing themselves to potent drugs. Clinicians should ask patients about the use of 'supplements' and report suspected adverse events to medicine agencies.
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